If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> EUROPEAN MEDICAL JOURNAL<br /> ISSN 2397-6764 Vol 3.1 · March 2018 · europeanmedical-journal.com<br /> CONTENTS<br /> EDITORIAL BOARD...................................................................................................................................... 4<br /> FEATURES<br /> • EUROPEAN LEAGUE AGAINST RHEUMATISM RECOMMENDATIONS FOR EARLY<br /> ARTHRITIS: WHAT HAS CHANGED?.................................................................................................. 12<br /> Michel Neidhart<br /> • CURRENT APPROACH TO THE TREATMENT OF CORONARY CHRONIC TOTAL<br /> OCCLUSIONS........................................................................................................................................... 17<br /> Leszek Bryniarski, Sławomir Surowiec<br /> SYMPOSIUM REVIEWS<br /> • INTERLEUKIN-23 IN PSORIASIS: INTEGRATING NEW THERAPIES IN THE CURRENT<br /> TREATM<a title="EMJ 3.1 2018 page 1" href="http://viewer.zmags.com/publication/4a00e3ac?page=1"> EUROPEAN MEDICAL JOURNAL ISSN 2397-6764 </a> <a title="EMJ 3.1 2018 page 2" href="http://viewer.zmags.com/publication/4a00e3ac?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ 3.1 2018 page 3" href="http://viewer.zmags.com/publication/4a00e3ac?page=3"> EUROPEAN MEDICAL JOURNAL • EARLY AND LONG-TER</a> <a title="EMJ 3.1 2018 page 4" href="http://viewer.zmags.com/publication/4a00e3ac?page=4"> EDITORIAL BOARD EDITOR-IN-CHIEF Prof Markus Pec</a> <a title="EMJ 3.1 2018 page 5" href="http://viewer.zmags.com/publication/4a00e3ac?page=5"> EUROPEAN MEDICAL JOURNAL AIMS AND SCOPE • T</a> <a title="EMJ 3.1 2018 page 6" href="http://viewer.zmags.com/publication/4a00e3ac?page=6"> Want a dose of health news? EUROPEAN MEDICAL JOU</a> <a title="EMJ 3.1 2018 page 7" href="http://viewer.zmags.com/publication/4a00e3ac?page=7"> Welcome Dear readers, A very warm welcome to t</a> <a title="EMJ 3.1 2018 page 8" href="http://viewer.zmags.com/publication/4a00e3ac?page=8"> 94 “I know I can re</a> <a title="EMJ 3.1 2018 page 9" href="http://viewer.zmags.com/publication/4a00e3ac?page=9"> Foreword Prof Mátyás Benyó University of Debre</a> <a title="EMJ 3.1 2018 page 10" href="http://viewer.zmags.com/publication/4a00e3ac?page=10"> Available now.</a> <a title="EMJ 3.1 2018 page 11" href="http://viewer.zmags.com/publication/4a00e3ac?page=11"> Featured inside: Congress Review + Review of M</a> <a title="EMJ 3.1 2018 page 12" href="http://viewer.zmags.com/publication/4a00e3ac?page=12"> EUROPEAN LEAGUE AGAINST RHEUMATISM RECOMMENDATION</a> <a title="EMJ 3.1 2018 page 13" href="http://viewer.zmags.com/publication/4a00e3ac?page=13"> care, incorporating escalating doses, intra-artic</a> <a title="EMJ 3.1 2018 page 14" href="http://viewer.zmags.com/publication/4a00e3ac?page=14"> as a targeted synthetic DMARD, which was re</a> <a title="EMJ 3.1 2018 page 15" href="http://viewer.zmags.com/publication/4a00e3ac?page=15"> single disease but a syndrome.17 This predi</a> <a title="EMJ 3.1 2018 page 16" href="http://viewer.zmags.com/publication/4a00e3ac?page=16"> 6. Luqmani R et al; British Society for </a> <a title="EMJ 3.1 2018 page 17" href="http://viewer.zmags.com/publication/4a00e3ac?page=17"> CURRENT APPROACH TO THE TREATMENT OF CORONARY </a> <a title="EMJ 3.1 2018 page 18" href="http://viewer.zmags.com/publication/4a00e3ac?page=18"> and less recurrent angina pectoris, when compared</a> <a title="EMJ 3.1 2018 page 19" href="http://viewer.zmags.com/publication/4a00e3ac?page=19"> Chronic coron ary occlusion </a> <a title="EMJ 3.1 2018 page 20" href="http://viewer.zmags.com/publication/4a00e3ac?page=20"> predictor of PCI failure after successful collate</a> <a title="EMJ 3.1 2018 page 21" href="http://viewer.zmags.com/publication/4a00e3ac?page=21"> Interact with us on social media. </a> <a title="EMJ 3.1 2018 page 22" href="http://viewer.zmags.com/publication/4a00e3ac?page=22"> INTERLEUKIN-23 IN PSORIASIS: INTEGRATING NEW T</a> <a title="EMJ 3.1 2018 page 23" href="http://viewer.zmags.com/publication/4a00e3ac?page=23"> An Immunologic Understanding of Cytokine Pathway</a> <a title="EMJ 3.1 2018 page 24" href="http://viewer.zmags.com/publication/4a00e3ac?page=24"> Blocking different targets in the immunopathogeni</a> <a title="EMJ 3.1 2018 page 25" href="http://viewer.zmags.com/publication/4a00e3ac?page=25"> Guselkumab Adalimumab 0 10 </a> <a title="EMJ 3.1 2018 page 26" href="http://viewer.zmags.com/publication/4a00e3ac?page=26"> been reported in a Phase II trial.12 In summary, </a> <a title="EMJ 3.1 2018 page 27" href="http://viewer.zmags.com/publication/4a00e3ac?page=27"> A survey of the use of biologic therapy recently </a> <a title="EMJ 3.1 2018 page 28" href="http://viewer.zmags.com/publication/4a00e3ac?page=28"> addition to reducing the skin inflammation, it wou</a> <a title="EMJ 3.1 2018 page 29" href="http://viewer.zmags.com/publication/4a00e3ac?page=29"> ustekinumab: Evidence from real life in a lar</a> <a title="EMJ 3.1 2018 page 30" href="http://viewer.zmags.com/publication/4a00e3ac?page=30"> FROM REGISTRY DATA TO REAL-LIFE EXPERIENCES: A H</a> <a title="EMJ 3.1 2018 page 31" href="http://viewer.zmags.com/publication/4a00e3ac?page=31"> data, primary patient data collection, </a> <a title="EMJ 3.1 2018 page 32" href="http://viewer.zmags.com/publication/4a00e3ac?page=32"> DERMBIO is a registry for patients with psoriasis</a> <a title="EMJ 3.1 2018 page 33" href="http://viewer.zmags.com/publication/4a00e3ac?page=33"> from PsoBest suggest biologics to be associated w</a> <a title="EMJ 3.1 2018 page 34" href="http://viewer.zmags.com/publication/4a00e3ac?page=34"> 10 (45.4%) who received adalimumab, 4 (18.2%) who</a> <a title="EMJ 3.1 2018 page 35" href="http://viewer.zmags.com/publication/4a00e3ac?page=35"> Unmet Needs There are a number of unmet needs in </a> <a title="EMJ 3.1 2018 page 36" href="http://viewer.zmags.com/publication/4a00e3ac?page=36"> she presented with pneumonia. In elderl</a> <a title="EMJ 3.1 2018 page 37" href="http://viewer.zmags.com/publication/4a00e3ac?page=37"> 23. Vilarrasa E et al. ORBIT (Outcome and </a> <a title="EMJ 3.1 2018 page 38" href="http://viewer.zmags.com/publication/4a00e3ac?page=38"> INTERLEUKIN-23 INHIBITION AS A STRATEGY TO TREAT </a> <a title="EMJ 3.1 2018 page 39" href="http://viewer.zmags.com/publication/4a00e3ac?page=39"> Receptor Cytokines Source </a> <a title="EMJ 3.1 2018 page 40" href="http://viewer.zmags.com/publication/4a00e3ac?page=40"> recently published data showing that psorias</a> <a title="EMJ 3.1 2018 page 41" href="http://viewer.zmags.com/publication/4a00e3ac?page=41"> with the maintained activation of Th17 cells and </a> <a title="EMJ 3.1 2018 page 42" href="http://viewer.zmags.com/publication/4a00e3ac?page=42"> Table 1: Response to ustekinumab in patients with</a> <a title="EMJ 3.1 2018 page 43" href="http://viewer.zmags.com/publication/4a00e3ac?page=43"> CD. Do you have any insights into the genetics, </a> <a title="EMJ 3.1 2018 page 44" href="http://viewer.zmags.com/publication/4a00e3ac?page=44"> 32. Neurath MF et al. Antibodies to interle</a> <a title="EMJ 3.1 2018 page 45" href="http://viewer.zmags.com/publication/4a00e3ac?page=45"> MISSION: RAPID ACTION AND LASTING REMISSION: </a> <a title="EMJ 3.1 2018 page 46" href="http://viewer.zmags.com/publication/4a00e3ac?page=46"> Mission Assigned: Rapid Onset and Lasting Remis</a> <a title="EMJ 3.1 2018 page 47" href="http://viewer.zmags.com/publication/4a00e3ac?page=47"> • Frequency of loose stools • </a> <a title="EMJ 3.1 2018 page 48" href="http://viewer.zmags.com/publication/4a00e3ac?page=48"> therapy (compared with no mucosal healing) was 4.</a> <a title="EMJ 3.1 2018 page 49" href="http://viewer.zmags.com/publication/4a00e3ac?page=49"> Treat-to-target Treat-to-target is a concep</a> <a title="EMJ 3.1 2018 page 50" href="http://viewer.zmags.com/publication/4a00e3ac?page=50"> patients with anti-TNF-α refractory UC by Week 2 </a> <a title="EMJ 3.1 2018 page 51" href="http://viewer.zmags.com/publication/4a00e3ac?page=51"> 12. van Assche G et al. Burden of disease </a> <a title="EMJ 3.1 2018 page 52" href="http://viewer.zmags.com/publication/4a00e3ac?page=52"> TARGETING MUCOSAL HEALING: </a> <a title="EMJ 3.1 2018 page 53" href="http://viewer.zmags.com/publication/4a00e3ac?page=53"> healing after 1 year of treatment was associated </a> <a title="EMJ 3.1 2018 page 54" href="http://viewer.zmags.com/publication/4a00e3ac?page=54"> and included only characteristics that contribute</a> <a title="EMJ 3.1 2018 page 55" href="http://viewer.zmags.com/publication/4a00e3ac?page=55"> 100 80 60 40 Number of patients with event/10</a> <a title="EMJ 3.1 2018 page 56" href="http://viewer.zmags.com/publication/4a00e3ac?page=56"> vedolizumab treatment duration of 3.2 years </a> <a title="EMJ 3.1 2018 page 57" href="http://viewer.zmags.com/publication/4a00e3ac?page=57"> of endoscopy and MRI for predicting intestin</a> <a title="EMJ 3.1 2018 page 58" href="http://viewer.zmags.com/publication/4a00e3ac?page=58"> EDITOR’S PICK My Editor’s Pick fo</a> <a title="EMJ 3.1 2018 page 59" href="http://viewer.zmags.com/publication/4a00e3ac?page=59"> time of ovulation. The rationale behind IUI</a> <a title="EMJ 3.1 2018 page 60" href="http://viewer.zmags.com/publication/4a00e3ac?page=60"> IUI should be avoided in a few conditions, either</a> <a title="EMJ 3.1 2018 page 61" href="http://viewer.zmags.com/publication/4a00e3ac?page=61"> endometriosis after laparoscopic correction of th</a> <a title="EMJ 3.1 2018 page 62" href="http://viewer.zmags.com/publication/4a00e3ac?page=62"> There are numerous studies demonstrating the</a> <a title="EMJ 3.1 2018 page 63" href="http://viewer.zmags.com/publication/4a00e3ac?page=63"> chances of conception; hence, the optimal volume </a> <a title="EMJ 3.1 2018 page 64" href="http://viewer.zmags.com/publication/4a00e3ac?page=64"> Table 3: Complications of intrauterine inseminati</a> <a title="EMJ 3.1 2018 page 65" href="http://viewer.zmags.com/publication/4a00e3ac?page=65"> Fallopian tube sperm perfusion was not foun</a> <a title="EMJ 3.1 2018 page 66" href="http://viewer.zmags.com/publication/4a00e3ac?page=66"> 23. Custers IM et al. Intrauterine inse</a> <a title="EMJ 3.1 2018 page 67" href="http://viewer.zmags.com/publication/4a00e3ac?page=67"> Coming soon. </a> <a title="EMJ 3.1 2018 page 68" href="http://viewer.zmags.com/publication/4a00e3ac?page=68"> EARLY AND LONG-TERM OUTCOMES AFTER NON-INTUBATED,</a> <a title="EMJ 3.1 2018 page 69" href="http://viewer.zmags.com/publication/4a00e3ac?page=69"> which similarly achieved satisfying results.3 In </a> <a title="EMJ 3.1 2018 page 70" href="http://viewer.zmags.com/publication/4a00e3ac?page=70"> anaesthetic technique (e.g., coagulopathy). In th</a> <a title="EMJ 3.1 2018 page 71" href="http://viewer.zmags.com/publication/4a00e3ac?page=71"> treatment (no longer than 4–6 weeks from the first</a> <a title="EMJ 3.1 2018 page 72" href="http://viewer.zmags.com/publication/4a00e3ac?page=72"> Table 1: Baseline, intraoperative, and immediate </a> <a title="EMJ 3.1 2018 page 73" href="http://viewer.zmags.com/publication/4a00e3ac?page=73"> Table 2: Postoperative mean ± standard deviation </a> <a title="EMJ 3.1 2018 page 74" href="http://viewer.zmags.com/publication/4a00e3ac?page=74"> A B 100 80 60 % 40 20 p=0.4 100 80 </a> <a title="EMJ 3.1 2018 page 75" href="http://viewer.zmags.com/publication/4a00e3ac?page=75"> 4. Crosa-Dorado VL et al. Treatment of dyspn</a> <a title="EMJ 3.1 2018 page 76" href="http://viewer.zmags.com/publication/4a00e3ac?page=76"> IMMUNOPATHOLOGY OF ALLERGIC CONJUNCTIVITIS </a> <a title="EMJ 3.1 2018 page 77" href="http://viewer.zmags.com/publication/4a00e3ac?page=77"> of immune cells in the conjunctiva constitu</a> <a title="EMJ 3.1 2018 page 78" href="http://viewer.zmags.com/publication/4a00e3ac?page=78"> that are complexed to major histocompatibili</a> <a title="EMJ 3.1 2018 page 79" href="http://viewer.zmags.com/publication/4a00e3ac?page=79"> Innate lymphoid cells (ILC), grouped into three c</a> <a title="EMJ 3.1 2018 page 80" href="http://viewer.zmags.com/publication/4a00e3ac?page=80"> A B Figure 2: Photographs of inferior palp</a> <a title="EMJ 3.1 2018 page 81" href="http://viewer.zmags.com/publication/4a00e3ac?page=81"> goblet cells in the conjunctiva8 and leukot</a> <a title="EMJ 3.1 2018 page 82" href="http://viewer.zmags.com/publication/4a00e3ac?page=82"> This mode of allergen-specific immunotherapy w</a> <a title="EMJ 3.1 2018 page 83" href="http://viewer.zmags.com/publication/4a00e3ac?page=83"> recruitment in a murine model of allergic conjunc</a> <a title="EMJ 3.1 2018 page 84" href="http://viewer.zmags.com/publication/4a00e3ac?page=84"> ADVANCES IN FAECAL DNA TESTING FOR COLOR</a> <a title="EMJ 3.1 2018 page 85" href="http://viewer.zmags.com/publication/4a00e3ac?page=85"> recommends that all adults have a colonoscopy for</a> <a title="EMJ 3.1 2018 page 86" href="http://viewer.zmags.com/publication/4a00e3ac?page=86"> Records identified through database searchi</a> <a title="EMJ 3.1 2018 page 87" href="http://viewer.zmags.com/publication/4a00e3ac?page=87"> used a multi-target stool DNA (sDNA) assay to a</a> <a title="EMJ 3.1 2018 page 88" href="http://viewer.zmags.com/publication/4a00e3ac?page=88"> Sensitivity and Specificity of Biomarkers Of the n</a> <a title="EMJ 3.1 2018 page 89" href="http://viewer.zmags.com/publication/4a00e3ac?page=89"> 6. Exact Science. The science behind the te</a> <a title="EMJ 3.1 2018 page 90" href="http://viewer.zmags.com/publication/4a00e3ac?page=90"> PSORIASIS: BEYOND THE SKIN *Aine Kel</a> <a title="EMJ 3.1 2018 page 91" href="http://viewer.zmags.com/publication/4a00e3ac?page=91"> disease is 7–12 years.6-8 A delay in the diagnosi</a> <a title="EMJ 3.1 2018 page 92" href="http://viewer.zmags.com/publication/4a00e3ac?page=92"> flares in psoriasis and is therefore best avoided.</a> <a title="EMJ 3.1 2018 page 93" href="http://viewer.zmags.com/publication/4a00e3ac?page=93"> sex with 260 healthy controls, psoriasis patients</a> <a title="EMJ 3.1 2018 page 94" href="http://viewer.zmags.com/publication/4a00e3ac?page=94"> such as erythrocyte mean cell volume, gamma- glut</a> <a title="EMJ 3.1 2018 page 95" href="http://viewer.zmags.com/publication/4a00e3ac?page=95"> 24. Bissonnette R et al. TNF-alpha antagonis</a> <a title="EMJ 3.1 2018 page 96" href="http://viewer.zmags.com/publication/4a00e3ac?page=96"> Inside you will find... Features + How to Imple</a> <a title="EMJ 3.1 2018 page 97" href="http://viewer.zmags.com/publication/4a00e3ac?page=97"> Read it today.</a> <a title="EMJ 3.1 2018 page 98" href="http://viewer.zmags.com/publication/4a00e3ac?page=98"> URTICARIA DIAGNOSIS *Tadech Boonpiy</a> <a title="EMJ 3.1 2018 page 99" href="http://viewer.zmags.com/publication/4a00e3ac?page=99"> specific immunoglobulin (Ig)E by exogenous</a> <a title="EMJ 3.1 2018 page 100" href="http://viewer.zmags.com/publication/4a00e3ac?page=100"> Mycoplasma pneumonia have also been attributed to</a> <a title="EMJ 3.1 2018 page 101" href="http://viewer.zmags.com/publication/4a00e3ac?page=101"> Autoinflammatory Syndromes Acquired autoinflammato</a> <a title="EMJ 3.1 2018 page 102" href="http://viewer.zmags.com/publication/4a00e3ac?page=102"> Table 1: Urticaria aetiologies and investigations</a> <a title="EMJ 3.1 2018 page 103" href="http://viewer.zmags.com/publication/4a00e3ac?page=103"> of onset, weekly frequency, duration of whe</a> <a title="EMJ 3.1 2018 page 104" href="http://viewer.zmags.com/publication/4a00e3ac?page=104"> CSU patients.32-36 Monitoring serum 25-hydrox</a> <a title="EMJ 3.1 2018 page 105" href="http://viewer.zmags.com/publication/4a00e3ac?page=105"> 13. Pezzolo E et al. Heat urticaria: A revi</a> <a title="EMJ 3.1 2018 page 106" href="http://viewer.zmags.com/publication/4a00e3ac?page=106"> WHEN THE NAIL APPEARANCE PLAYS TRICKS: A CASE O</a> <a title="EMJ 3.1 2018 page 107" href="http://viewer.zmags.com/publication/4a00e3ac?page=107"> Figure 1: Longitudinal melanonychia of the first d</a> <a title="EMJ 3.1 2018 page 108" href="http://viewer.zmags.com/publication/4a00e3ac?page=108"> A B Figure 3: Longitudinal biopsy of the lesion</a> <a title="EMJ 3.1 2018 page 109" href="http://viewer.zmags.com/publication/4a00e3ac?page=109"> nevus, which can be congenital or acquired, is th</a> <a title="EMJ 3.1 2018 page 110" href="http://viewer.zmags.com/publication/4a00e3ac?page=110"> However, these features can also be seen in nail </a> <a title="EMJ 3.1 2018 page 111" href="http://viewer.zmags.com/publication/4a00e3ac?page=111"> POSITIVE VESSEL REMODELLING *Franz X. Kleber,1 </a> <a title="EMJ 3.1 2018 page 112" href="http://viewer.zmags.com/publication/4a00e3ac?page=112"> in vascular medicine. Most cardiologists </a> <a title="EMJ 3.1 2018 page 113" href="http://viewer.zmags.com/publication/4a00e3ac?page=113"> restenosis settings; however, a clinical pro</a> <a title="EMJ 3.1 2018 page 114" href="http://viewer.zmags.com/publication/4a00e3ac?page=114"> LIMITATIONS Dissections One might consider the</a> <a title="EMJ 3.1 2018 page 115" href="http://viewer.zmags.com/publication/4a00e3ac?page=115"> 11. Nakazawa G et al. Pathophysiology of vascular</a> <a title="EMJ 3.1 2018 page 116" href="http://viewer.zmags.com/publication/4a00e3ac?page=116"> OSTEOARTHRITIS AND AGEING *Ana M. Valdes,1,</a> <a title="EMJ 3.1 2018 page 117" href="http://viewer.zmags.com/publication/4a00e3ac?page=117"> defined pathologically, radiographically, or clini</a> <a title="EMJ 3.1 2018 page 118" href="http://viewer.zmags.com/publication/4a00e3ac?page=118"> in prevalence and progression of cartilage </a> <a title="EMJ 3.1 2018 page 119" href="http://viewer.zmags.com/publication/4a00e3ac?page=119"> These data, therefore, prove the functional relev</a> <a title="EMJ 3.1 2018 page 120" href="http://viewer.zmags.com/publication/4a00e3ac?page=120"> overproduction of pro-inflammatory cytokines and M</a> <a title="EMJ 3.1 2018 page 121" href="http://viewer.zmags.com/publication/4a00e3ac?page=121"> Patients with the presence of one or two frailty </a> <a title="EMJ 3.1 2018 page 122" href="http://viewer.zmags.com/publication/4a00e3ac?page=122"> and OA pain to systemic inflammation, development </a> <a title="EMJ 3.1 2018 page 123" href="http://viewer.zmags.com/publication/4a00e3ac?page=123"> Disord. 2001;25(5):622-7. 42. Slemenda C et</a> <a title="EMJ 3.1 2018 page 124" href="http://viewer.zmags.com/publication/4a00e3ac?page=124"> INSOMNIA IN THE AGEING </a> <a title="EMJ 3.1 2018 page 125" href="http://viewer.zmags.com/publication/4a00e3ac?page=125"> lost. The decreased expression of SCN genes that </a> <a title="EMJ 3.1 2018 page 126" href="http://viewer.zmags.com/publication/4a00e3ac?page=126"> being able to return to sleep, even with adequate</a> <a title="EMJ 3.1 2018 page 127" href="http://viewer.zmags.com/publication/4a00e3ac?page=127"> Organisations such as the American Geriatric</a> <a title="EMJ 3.1 2018 page 128" href="http://viewer.zmags.com/publication/4a00e3ac?page=128"> the results.56-58 Evidence regarding the eff</a> <a title="EMJ 3.1 2018 page 129" href="http://viewer.zmags.com/publication/4a00e3ac?page=129"> perspective on insomnia treatment. Psychiat</a> <a title="EMJ 3.1 2018 page 130" href="http://viewer.zmags.com/publication/4a00e3ac?page=130"> What’s New Fully Mature, Laboratory-Grown Human</a> <a title="EMJ 3.1 2018 page 131" href="http://viewer.zmags.com/publication/4a00e3ac?page=131"> European Medical Journal Regulating Blood Vesse</a> <a title="EMJ 3.1 2018 page 132" href="http://viewer.zmags.com/publication/4a00e3ac?page=132"> What’s New Promising New Therapy Option for Adult</a> <a title="EMJ 3.1 2018 page 133" href="http://viewer.zmags.com/publication/4a00e3ac?page=133"> European Medical Journal Ulcerative Colitis Remis</a> <a title="EMJ 3.1 2018 page 134" href="http://viewer.zmags.com/publication/4a00e3ac?page=134"> Never miss an update again. J</a>